Biotechnology - Asia-Pacific, AstraZeneca

Filter

Current filters:

Asia-PacificAstraZeneca

Popular Filters

WuXi AppTec opens first cGMP biologics facility in China

21-10-2012

China's WuXi AppTec recently hosted an inaugural Global Monoclonal Antibody Summit in conjunction with…

Asia-PacificAstraZenecaBiotechnologyProductionResearchWuXi Apptec

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan

17-04-2012

Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Back to top